Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Advanced Nonhematologic Malignancies 1Advanced Non-hematologic Malignancies 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
TAK 733 × Clear all
NCT01613261 2013-11-01

Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1 Withdrawn

Advanced Nonhematologic Malignancies

NCT00948467 2013-07-02

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
51 enrolled
Dermatologic

Advanced Non-hematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡